Cargando…

Eating the Dead to Keep Atherosclerosis at Bay

Atherosclerosis is the primary cause of coronary heart disease (CHD), ischemic stroke, and peripheral arterial disease. Despite effective lipid-lowering therapies and prevention programs, atherosclerosis is still the leading cause of mortality in the United States. Moreover, the prevalence of CHD in...

Descripción completa

Detalles Bibliográficos
Autores principales: Brophy, Megan L., Dong, Yunzhou, Wu, Hao, Rahman, H. N. Ashiqur, Song, Kai, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5277199/
https://www.ncbi.nlm.nih.gov/pubmed/28194400
http://dx.doi.org/10.3389/fcvm.2017.00002
_version_ 1782502424025497600
author Brophy, Megan L.
Dong, Yunzhou
Wu, Hao
Rahman, H. N. Ashiqur
Song, Kai
Chen, Hong
author_facet Brophy, Megan L.
Dong, Yunzhou
Wu, Hao
Rahman, H. N. Ashiqur
Song, Kai
Chen, Hong
author_sort Brophy, Megan L.
collection PubMed
description Atherosclerosis is the primary cause of coronary heart disease (CHD), ischemic stroke, and peripheral arterial disease. Despite effective lipid-lowering therapies and prevention programs, atherosclerosis is still the leading cause of mortality in the United States. Moreover, the prevalence of CHD in developing countries worldwide is rapidly increasing at a rate expected to overtake those of cancer and diabetes. Prominent risk factors include the hardening of arteries and high levels of cholesterol, which lead to the initiation and progression of atherosclerosis. However, cell death and efferocytosis are critical components of both atherosclerotic plaque progression and regression, yet, few currently available therapies focus on these processes. Thus, understanding the causes of cell death within the atherosclerotic plaque, the consequences of cell death, and the mechanisms of apoptotic cell clearance may enable the development of new therapies to treat cardiovascular disease. Here, we review how endoplasmic reticulum stress and cholesterol metabolism lead to cell death and inflammation, how dying cells affect plaque progression, and how autophagy and the clearance of dead cells ameliorates the inflammatory environment of the plaque. In addition, we review current research aimed at alleviating these processes and specifically targeting therapeutics to the site of the plaque.
format Online
Article
Text
id pubmed-5277199
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-52771992017-02-13 Eating the Dead to Keep Atherosclerosis at Bay Brophy, Megan L. Dong, Yunzhou Wu, Hao Rahman, H. N. Ashiqur Song, Kai Chen, Hong Front Cardiovasc Med Cardiovascular Medicine Atherosclerosis is the primary cause of coronary heart disease (CHD), ischemic stroke, and peripheral arterial disease. Despite effective lipid-lowering therapies and prevention programs, atherosclerosis is still the leading cause of mortality in the United States. Moreover, the prevalence of CHD in developing countries worldwide is rapidly increasing at a rate expected to overtake those of cancer and diabetes. Prominent risk factors include the hardening of arteries and high levels of cholesterol, which lead to the initiation and progression of atherosclerosis. However, cell death and efferocytosis are critical components of both atherosclerotic plaque progression and regression, yet, few currently available therapies focus on these processes. Thus, understanding the causes of cell death within the atherosclerotic plaque, the consequences of cell death, and the mechanisms of apoptotic cell clearance may enable the development of new therapies to treat cardiovascular disease. Here, we review how endoplasmic reticulum stress and cholesterol metabolism lead to cell death and inflammation, how dying cells affect plaque progression, and how autophagy and the clearance of dead cells ameliorates the inflammatory environment of the plaque. In addition, we review current research aimed at alleviating these processes and specifically targeting therapeutics to the site of the plaque. Frontiers Media S.A. 2017-01-30 /pmc/articles/PMC5277199/ /pubmed/28194400 http://dx.doi.org/10.3389/fcvm.2017.00002 Text en Copyright © 2017 Brophy, Dong, Wu, Rahman, Song and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Brophy, Megan L.
Dong, Yunzhou
Wu, Hao
Rahman, H. N. Ashiqur
Song, Kai
Chen, Hong
Eating the Dead to Keep Atherosclerosis at Bay
title Eating the Dead to Keep Atherosclerosis at Bay
title_full Eating the Dead to Keep Atherosclerosis at Bay
title_fullStr Eating the Dead to Keep Atherosclerosis at Bay
title_full_unstemmed Eating the Dead to Keep Atherosclerosis at Bay
title_short Eating the Dead to Keep Atherosclerosis at Bay
title_sort eating the dead to keep atherosclerosis at bay
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5277199/
https://www.ncbi.nlm.nih.gov/pubmed/28194400
http://dx.doi.org/10.3389/fcvm.2017.00002
work_keys_str_mv AT brophymeganl eatingthedeadtokeepatherosclerosisatbay
AT dongyunzhou eatingthedeadtokeepatherosclerosisatbay
AT wuhao eatingthedeadtokeepatherosclerosisatbay
AT rahmanhnashiqur eatingthedeadtokeepatherosclerosisatbay
AT songkai eatingthedeadtokeepatherosclerosisatbay
AT chenhong eatingthedeadtokeepatherosclerosisatbay